Advanced search
Publication Cover
Future Medicinal Chemistry Volume 2, 2010 - Issue 5
Submit an article Journal homepage
453
Views
1
CrossRef citations to date
0
Altmetric
Review

Screening Technologies for Ion Channel Drug Discovery

Georg C Terstappen1 Siena Biotech S.p.A., Strada del Petriccio e Belriguardo 35, 53100Siena, ItalyCorrespondence[email protected]
View further author information
,
Renza Roncarati1 Siena Biotech S.p.A., Strada del Petriccio e Belriguardo 35, 53100Siena, ItalyView further author information
,
John Dunlop2 Neuroscience Research Unit, Pfizer, Eastern Point Road, Groton, CT, USAView further author information
&
Ravikumar Peri2 Neuroscience Research Unit, Pfizer, Eastern Point Road, Groton, CT, USACorrespondence[email protected]
View further author information
Pages 715-730 | Published online: 12 May 2010

Bibliography

  • Venter JC , AdamsMD, MyersEWet al. The sequence of the human genome. Science 291(5507), 1304–1351 (2001).
  • Lehmann-Horn F , RudelR, DenglerR, LorkovicH, HaassA, RickerK. Membrane defects in paramyotonia congenita with and without myotonia in a warm environment.Muscle Nerve4(5), 396–406 (1981).
  • Schwartzkroin PA , WylerAR. Mechanisms underlying epileptiform burst discharge.Ann. Neurol.7(2), 95–107 (1980).
  • Riordan JR , RommensJM, KeremBet al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922), 1066–1073 (1989).
  • Griggs RC , NuttJG. Episodic ataxias as channelopathies.Ann. Neurol.37(3), 285–287 (1995).
  • Ashcroft FM . From molecule to malady.Nature440(7083), 440–447 (2006).
  • Imming P , SinningC, MeyerA. Drugs, their targets and the nature and number of drug targets.Nat. Rev. Drug Discov.5(10), 821–834 (2006).
  • Hamill OP , MartyA, NeherE, SakmannB, SigworthFJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.Pflugers Arch.391(2), 85–100 (1981).
  • Bouevitch O , LewisA, PinevskyI, WuskellJP, LoewLM. Probing membrane potential with nonlinear optics.Biophys. J.65(2), 672–679 (1993).
  • Knisley SB , BlitchingtonTF, HillBCet al. Optical measurements of transmembrane potential changes during electric field stimulation of ventricular cells. Circ. Res. 72(2), 255–270 (1993).
  • Epps DE , WolfeML, GroppiV. Characterization of the steady-state and dynamic fluorescence properties of the potential-sensitive dye bis-(1,3-dibutylbarbituric acid)trimethine oxonol (Dibac4(3)) in model systems and cells. Chem. Phys. Lipids69(2), 137–150 (1994).
  • Schroeder KS , NeagleBD. FLiPR: a new instrument for accurate high-throughput optical screening.J. Biomol. Screen.1, 75–80 (1996).
  • Holevinsky KO , FanZ, FrameM, MakielskiJC, GroppiV, NelsonDJ. ATP-sensitive K+ channel opener acts as a potent Cl- channel inhibitor in vascular smooth muscle cells. J. Membr. Biol.137(1), 59–70 (1994).
  • Dorn A , HermannF, EbnethAet al. Evaluation of a high-throughput fluorescence assay method for HERG potassium channel inhibition. J. Biomol. Screen. 10(4), 339–347 (2005).
  • Gopalakrishnan M , MolinariEJ, ShiehCCet al. Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K+ channel Kir6.2 combination expressed in HEK-293 cells. Br. J. Pharmacol. 129(7), 1323–1332 (2000).
  • Terstappen GC , PellacaniA, AldegheriLet al. The antidepressant fluoxetine blocks the human small conductance calcium-activated potassium channels SK1, SK2 and SK3. Neurosci. Lett. 346(1–2), 85–88 (2003).
  • Whiteaker KL , Davis-TaberR, ScottVE, GopalakrishnanM. Fluorescence-based functional assay for sarcolemmal ATP-sensitive potassium channel activation in cultured neonatal rat ventricular myocytes.J. Pharmacol. Toxicol. Methods46(1), 45–50 (2001).
  • Whiteaker KL , GopalakrishnanSM, GroebeDet al. Validation of FLiPR membrane potential dye for high throughput screening of potassium channel modulators. J. Biomol. Screen. 6(5), 305–312 (2001).
  • Vasilyev DV , ShanQJ, LeeYTet al. A novel high-throughput screening assay for HCN channel blocker using membrane potential-sensitive dye and FLiPR. J. Biomol. Screen. 14(9), 1119–1128 (2009).
  • Benjamin ER , PruthiF, OlanrewajuSet al. State-dependent compound inhibition of Nav1.2 sodium channels using the FLiPR Vm dye: on-target and off-target effects of diverse pharmacological agents. J. Biomol. Screen. 11(1), 29–39 (2006).
  • Joesch C , GuevarraE, ParelSPet al. Use of FLiPR membrane potential dyes for validation of high-throughput screening with the FLiPR and microARCS technologies: identification of ion channel modulators acting on the GABAA receptor. J. Biomol. Screen. 13(3), 218–228 (2008).
  • Slack M , KirchhoffC, MollerC, WinklerD, NetzerR. Identification of novel Kv1.3 blockers using a fluorescent cell-based ion channel assay. J. Biomol. Screen.11(1), 57–64 (2006).
  • Gonzalez JE , TsienRY. Voltage sensing by fluorescence resonance energy transfer in single cells.Biophys. J.69(4), 1272–1280 (1995).
  • Gonzalez JE , TsienRY. Improved indicators of cell membrane potential that use fluorescence resonance energy transfer.Chem. Biol.4(4), 269–277 (1997).
  • Falconer M , SmithF, Surah-NarwalSet al. High-throughput screening for ion channel modulators. J. Biomol. Screen. 7(5), 460–465 (2002).
  • Felix JP , WilliamsBS, PriestBTet al. Functional assay of voltage-gated sodium channels using membrane potential-sensitive dyes. Assay Drug Dev. Technol. 2(3), 260–268 (2004).
  • Liu CJ , PriestBT, BugianesiRMet al. A high-capacity membrane potential FRET-based assay for NaV1.8 channels. Assay Drug Dev. Technol. 4(1), 37–48 (2006).
  • Solly K , CassadayJ, FelixJPet al. Miniaturization and HTS of a FRET-based membrane potential assay for Kir channel inhibitors. Assay Drug Dev. Technol. 6(2), 225–234 (2008).
  • Willow M , KuenzelEA, CatterallWA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine.Mol. Pharmacol.25(2), 228–234 (1984).
  • Rasmussen CA Jr, Sutko JL, Barry WH. Effects of ryanodine and caffeine on contractility, membrane voltage, and calcium exchange in cultured heart cells. Circ. Res.60(4), 495–504 (1987).
  • Rasmussen H , TakuwaY, ParkS. Protein kinase C in the regulation of smooth muscle contraction.FASEB J.1(3), 177–185 (1987).
  • Weir SW , WestonAH. The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on 86Rb efflux in rat blood vessels. Br. J. Pharmacol.88(1), 121–128 (1986).
  • Terstappen GC . Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay.Anal. Biochem.272(2), 149–155 (1999).
  • Terstappen GC . Nonradioactive rubidium ion efflux assay and its applications in drug discovery and development.Assay Drug Dev. Technol.2(5), 553–559 (2004).
  • Terstappen GC . Nonradioactive rubidium efflux assay technology for screening of ion channels. In: Label-Free Assay Technologies for Drug Discovery. Cooper M, Mayer L (Eds). Wiley-VCH, Weinheim, Germany (2010) (In Press).
  • Rezazadeh S , HeskethJC, FedidaD. Rb+ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ efflux assay. J. Biomol. Screen.9(7), 588–597 (2004).
  • Tang W , KangJ, WuXet al. Development and evaluation of high throughput functional assay methods for HERG potassium channel. J. Biomol. Screen. 6(5), 325–331 (2001).
  • Chaudhary KW , O‘NealJM, MoZL, FerminiB, GallavanRH, BahinskiA. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade.Assay Drug Dev. Technol.4(1), 73–82 (2006).
  • Trivedi S , DekermendjianK, JulienRet al. Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulators. Assay Drug Dev. Technol. 6(2), 167–179 (2008).
  • Gill S , GillR, XieY, WicksD, LiangD. Development and validation of HTS flux assay for endogenously expressed chloride channels in a CHO-K1 cell line.Assay Drug Dev. Technol.4(1), 65–71 (2006).
  • Kasner SE , GanzMB. Regulation of intracellular potassium in mesangial cells: a fluorescence analysis using the dye, PBFI.Am. J. Physiol.262(3 Pt 2), F462–467 (1992).
  • Minta A , TsienRY. Fluorescent indicators for cytosolic sodium.J. Biol. Chem.264(32), 19449–19457 (1989).
  • Verkman AS , TaklaR, SeftonB, BasbaumC, WiddicombeJH. Quantitative fluorescence measurement of chloride transport mechanisms in phospholipid vesicles.Biochemistry28(10), 4240–4244 (1989).
  • Grynkiewicz G , PoenieM, TsienRY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem.260(6), 3440–3450 (1985).
  • Mattheakis LC , SavchenkoA. Assay technologies for screening ion channel targets.Curr. Opin. Drug Discov. Devel.4(1), 124–134 (2001).
  • Song Y , BuelowB, PerraudAL, ScharenbergAM. Development and validation of a cell-based high-throughput screening assay for TRPM2 channel modulators.J. Biomol. Screen.13(1), 54–61 (2008).
  • Dai G , HaedoRJ, WarrenVAet al. A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. Assay Drug Dev. Technol. 6(2), 195–212 (2008).
  • Weaver CD , HardenD, DworetzkySI, RobertsonB, KnoxRJ. A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells.J. Biomol. Screen.9(8), 671–677 (2004).
  • Titus SA , BeachamD, ShahaneSAet al. A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Anal. Biochem. 394(1), 30–38 (2009).
  • Kiss L , BennettPB, UebeleVNet al. High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev. Technol. 1(1,2), 127–135 (2003).
  • Schroeder K , NeagleB, TreziseDJ, WorleyJ. Ionworks HT: a new high-throughput electrophysiology measurement platform.J. Biomol. Screen.8(1), 50–64 (2003).
  • Finkel A , WittelA, YangN, HandranS, HughesJ, CostantinJ. Population patch clamp improves data consistency and success rates in the measurement of ionic currents.J. Biomol. Screen.11(5), 488–496 (2006).
  • Dunlop J , BowlbyM, PeriR, VasilyevD, AriasR. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology.Nat. Rev. Drug Discov.7(4), 358–368 (2008).
  • Lu Q , AnWF. Impact of novel screening technologies on ion channel drug discovery.Comb. Chem. High Throughput Screen.11(3), 185–194 (2008).
  • Bridgland-Taylor MH , HargreavesAC, EasterAet al. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J. Pharmacol. Toxicol. Methods 54(2), 189–199 (2006).
  • Sorota S , ZhangXS, MargulisM, TuckerK, PriestleyT. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen.Assay Drug Dev. Technol.3(1), 47–57 (2005).
  • John VH , DaleTJ, HollandsECet al. Novel 384-well population patch clamp electrophysiology assays for Ca2+-activated K+ channels. J. Biomol. Screen. 12(1), 50–60 (2007).
  • Jow F , ShenR, ChandaPet al. Validation of a medium-throughput electrophysiological assay for KCNQ2/3 channel enhancers using IonWorks HT. J. Biomol. Screen. 12(8), 1059–1067 (2007).
  • Xie X , Van DeusenAL, VitkoIet al. Validation of high throughput screening assays against three subtypes of Cav3 T-type channels using molecular and pharmacologic approaches. Assay Drug Dev. Technol.5(2), 191–203 (2007).
  • Lee YT , VasilyevDV, ShanQJ, DunlopJ, MayerS, BowlbyMR. Novel pharmacological activity of loperamide and CP-339,818 on human HCN channels characterized with an automated electrophysiology assay.Eur. J. Pharmacol.581(1–2), 97–104 (2008).
  • Harmer AR , Abi-GergesN, EasterAet al. Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks. J. Pharmacol. Toxicol. Methods 57(1), 30–41 (2008).
  • Castle N , PrintzenhoffD, ZellmerS, AntonioB, WickendenA, SilviaC. Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms.Comb. Chem. High Throughput Screen.12(1), 107–122 (2009).
  • Cox JJ , ReimannF, NicholasAKet al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444(7121), 894–898 (2006).
  • Goldberg YP , MacFarlaneJ, MacDonaldMLet al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin. Genet. 71(4), 311–319 (2007).
  • Dunlop J , BowlbyM, PeriRet al. Ion channel screening. Comb. Chem. High Throughput Screen. 11(7), 514–522 (2008).
  • Clare JJ , ChenMX, DownieDL, TreziseDJ, PowellAJ. Use of planar array electrophysiology for the development of robust ion channel cell lines.Comb. Chem. High Throughput Screen.12(1), 96–106 (2009).
  • Dubin AE , NasserN, RohrbacherJet al. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J. Biomol. Screen. 10(2), 168–181 (2005).
  • Ghetti A , GuiaA, XuJ. Automated voltage-clamp technique.Methods Mol. Biol.403, 59–69 (2007).
  • Asmild M , OswaldN, KrzywkowskiKMet al. Upscaling and automation of electrophysiology: toward high throughput screening in ion channel drug discovery. Receptors Channels 9(1), 49–58 (2003).
  • Beck EJ , HutchinsonTL, QinN, FloresCM, LiuY. Development and validation of a secondary screening assay for TRPM8 antagonists using QPatch HT.Assay Drug Dev. Technol.
  • Mathes C , FriisS, FinleyM, LiuY. QPatch: the missing link between HTS and ion channel drug discovery.Comb. Chem. High Throughput Screen.12(1), 78–95 (2009).
  • McPate M , LilleyS, GoslingM, FriisS, JacobsenRB, TranterP. Evaluation of the QPatch HT and HTX systems as methods for ion channel screening.Biophys. J.98(3, Suppl. 1), 340a (2010).
  • Farre C , StoelzleS, HaarmannC, GeorgeM, BruggemannA, FertigN. Automated ion channel screening: patch clamping made easy.Expert Opin. Ther. Targets11(4), 557–565 (2007).
  • Brueggemann A , GeorgeM, KlauMet al. Ion channel drug discovery and research: the automated nano-patch-clamp technology. Curr. Drug Discov. Technol. 1(1), 91–96 (2004).
  • Bruggemann A , GeorgeM, KlauMet al. High quality ion channel analysis on a chip with the NPC technology. Assay Drug Dev. Technol. 1(5), 665–673 (2003).
  • Farre C , HaythornthwaiteA, HaarmannCet al. Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology. Comb. Chem. High Throughput Screen. 12(1), 24–37 (2009).
  • Balasubramanian B , ImredyJP, KimD, PennimanJ, LagruttaA, SalataJJ. Optimization of Cav1.2 screening with an automated planar patch clamp platform. J. Pharmacol. Toxicol. Methods59(2), 62–72 (2009).
  • Guo L , GuthrieH. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.J. Pharmacol. Toxicol. Methods52(1), 123–135 (2005).
  • Korsgaard MP , StrobaekD, ChristophersenP. Automated planar electrode electrophysiology in drug discovery: examples of the use of QPatch in basic characterization and high content screening on Nav, K(Ca)2.3, and Kv11.1 channels. Comb. Chem. High Throughput Screen12(1), 51–63 (2009).
  • Kutchinsky J , FriisS, AsmildMet al. Characterization of potassium channel modulators with QPatch automated patch-clamp technology: system characteristics and performance. Assay Drug Dev. Technol. 1(5), 685–693 (2003).
  • Tao H , Santa AnaD, GuiaAet al. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev. Technol.2(5), 497–506 (2004).
  • Mo ZL , FaxelT, YangYS, GallavanR, MessingD, BahinskiA. Effect of compound plate composition on measurement of hERG current IC(50) using PatchXpress.J. Pharmacol. Toxicol. Methods60(1), 39–44 (2009).
  • Ratliff KS , PetrovA, EiermannGJet al. An automated electrophysiology serum shift assay for K(V) channels. Assay Drug Dev. Technol. 6(2), 243–253 (2008).
  • Jones KA , GarbatiN, ZhangH, LargeCH. Automated patch clamping using the QPatch.Methods Mol. Biol.565, 209–223 (2009).
  • Schroder RL , FriisS, SunesenM, MathesC, WillumsenNJ. Automated patch-clamp technique: increased throughput in functional characterization and in pharmacological screening of small-conductance Ca2+ release-activated Ca2+ channels. J. Biomol. Screen.13(7), 638–647 (2008).
  • Dunlop J , RoncaratiR, JowBet al. In vitro screening strategies for nicotinic receptor ligands. Biochem. Pharmacol.74(8), 1172–1181 (2007).
  • Friis S , MathesC, SunesenM, BowlbyMR, DunlopJ. Characterization of compounds on nicotinic acetylcholine receptor α7 channels using higher throughput electrophysiology.J. Neurosci. Methods177(1), 142–148 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.